OPTI.GB OptiBiotix Health plc

TIDMOPTI

RNS Number : 8392Z

OptiBiotix Health PLC

20 September 2022

OptiBiotix Health plc

("OptiBiotix" or the "Company" or the "Group")

Launch of GoFigure range with Apollo Hospitals & Pharmacies in India

OptiBiotix Ltd, a wholly owned subsidiary of OptiBiotix Health plc (AIM: OPTI) and a life sciences business developing patented science and human study-based compounds that modulate the microbiome to address a range of health related issues such as metabolic syndrome and diabetes, systemic low-grade inflammation, obesity, cardiovascular disease, high cholesterol and healthy aging announces, further to the exclusive sales agreement announced 9 December 2021, that its GoFigure range was officially launched by Apollo Hospitals & Pharmacies on 18 September 2022.

Apollo Pharmacies ( https://www.apollopharmacy.in/ ), owned by Apollo Hospitals through Apollo Healthco, is the largest and most trusted branded pharmacy networks, with 5,000 pharmacy outlets throughout India.

GoFigure is OptiBiotix's direct-to-consumer (D2C) ( https://gofigurediet.com/ ) range of weight management products which combines various meal replacement, healthy snacking options and powdered beverages containing its multi award winning weight management ingredient SlimBiome (R) . The GoFigure portfolio is available for retailers and pharmacies worldwide.

SlimBiome (R) is OptiBiotix's proprietary weight management aid. It supports people on a calorie restricted diet to lose weight faster. Human studies show that it reduces hunger, makes you feel full for longer, reduces food cravings and uniquely changes the microbiome over time in the direction of a lean person's microbiome. SlimBiome (R) carries a wealth of health claims and is available to formulators worldwide.

Apollo's GoFigure product launch consists of meal replacement shakes and powdered beverage shots and will be expanded over time with extra flavours and new product forms such as bars. OptiBiotix is responsible for product development and manufacturing locally in India and has tailored the range jointly with the Apollo team to suit the unique needs of Indian consumers.

The launch has taken place both in store as well as on the newly created Apollo 24|7 online customer platform. Initially the product will be available in 120 top stores in major cities across India and then expanded from there.

René Kamminga, C EO of O pti B i oti x Limited, c o mmented : "We are very pleased that our GoFigure products are now available to the consumer in India through Apollo Pharmacies, a leading pharmacy chain in India. Our GoFigure range of weight management products have been specifically formulated to support consumers on a weight loss journey by reducing hunger and food cravings as well as modifying the gut microbiome in the direction of a lean person. 18 September marks both the 40(th) anniversary of the group and the 5000(th) pharmacy opening for Apollo so it is significant to launch on this memorable day. This launch is another important step in building sales and brand presence for OptiBiotix's solutions with major partners around the world."

This announcement contains inside information for the purposes of UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

 
 OptiBiotix Health plc                                       www.optibiotix.com 
 Stephen O'Hara, Chief Executive                     Contact via Walbrook below 
 OptiBiotix Health Ltd 
  Rene Kamminga 
 
 Cairn Financial Advisers LLP (NOMAD)                        Tel: 020 7213 0880 
 Liam Murray / Jo Turner / Ludovico Lazzaretti 
 
 Cenkos Securities plc (Broker)                              Tel: 020 7397 8900 
 Callum Davidson / Neil McDonald 
 Michael Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                                             Mob: 07876 741 001 
 Anna Dunphy 
 
 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identi ed by their use of terms and phrases such as "believe", "could", "should" "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements re ect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFLFFLAEIDLIF

(END) Dow Jones Newswires

September 20, 2022 02:00 ET (06:00 GMT)

OptiBiotix Health (AQSE:OPTI.GB)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024

OptiBiotix Health (AQSE:OPTI.GB)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024